|Articles|October 14, 2022
Scalable rubella production in scale-X™ bioreactor with MRC-5 cells
Author(s)Univercells Technologies
This application note demonstrates the successful transfer, optimization and scale-up of the Rubella vaccine manufacturing process from static flasks to scale-X™ bioreactors.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
Ultragenyx Phase III Data Reveal Limits of Bone Density Endpoints in Rare Bone Disease
2
Building Robust Biomanufacturing Networks for the Next Wave of Therapies
3
Biopharma’s 2025 Transformation: A Recap of Our Top 10 Articles
4
Insuring Novel Biologic Development Against Geopolitical Developments: Part Three of Three with Abzena
5